Overview
- Jeito II reached a final close at $1.2 billion, topping its €1 billion goal and lifting the firm’s assets under management to €1.6 billion.
- The fund targets 15 to 20 clinical-stage companies and can commit up to €150 million to each to carry programs through late testing.
- Jeito says it has already invested across obesity, oncology, neurology, autoimmune and inflammatory diseases, cardiometabolic conditions, and reproductive medicine.
- Backers include investors from Europe, North America, and Asia such as sovereign funds, insurers, pension funds, corporate groups, banks, family offices, foundations, and endowments.
- The firm cites recent exits—EyeBio sold to Merck for up to $3 billion and HI-Bio to Biogen for up to $1.8 billion—as evidence of its model as large drug makers face patent losses and seek new treatments from smaller biotechs.